Published in
Oxford University Press, The Oncologist, 6(26), p. e1083-e1084, 2021
DOI: 10.1002/onco.13710
Links
Tools
Regarding “ Hepatitis B surface antigen positivity is an independent unfavorable prognostic factor in diffuse large B‐cell lymphoma in the rituximab era”
Journal article published in 2021 by
Marco Picardi 
,
Claudia Giordano ,
Roberta Della Pepa ,
Novella Pugliese ,
Aldo Leone,
Giuseppe Delle Cave,
Rossella Iula,
Giuseppe Gentile ,
Fabrizio Pane
,
Claudia Giordano ,
Roberta Della Pepa ,
Novella Pugliese ,
Aldo Leone,
Giuseppe Delle Cave,
Rossella Iula,
Giuseppe Gentile ,
Fabrizio Pane
This paper is made freely available by the publisher.
Full text: Download
Data provided by 
Abstract
This letter to the editor remarks on the article by Cheng et al., which reported results of a retrospective study that assessed 5-year progression-free and overall survival (OS) of 98 patients with hepatitis B surface antigen–seropositive patients receiving R-CHOP-21 as remission induction for diffuse large B-cell lymphoma.